^
    Back
    Association details:
    Biomarker:AHNAK2 mutation
    Cancer:Non Small Cell Lung Cancer
    Drug Class:Immunotherapy
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Front Oncol
    Title:

    Deleterious AHNAK2 Mutation as a Novel Biomarker for Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer

    Published date:
    03/10/2022
    Excerpt:
    We found that the mutation of AHNAK2 was statistical significantly associated with higher ORR (Figure 2C), suggesting that AHNAK2 mutation might predict an improved clinical outcome for NSCLC patients treated with ICIs.
    DOI:
    https://doi.org/10.3389/fonc.2022.798401